The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia
There is no vaccine or antiviral treatment for human coronavirus, so this study aims to
evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19
pneumonia.
Drug: Darunavir and Cobicistat
Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
Inclusion Criteria:
- The participants were diagnosed as COVID-19 pneumonia, according to the notice on
printing and distributing the diagnosis and treatment plan of pneumonia with new
coronavirus infection (trial version 4 or update version) made by National Health
Commission of the People's Republic of China.
- Written the informed consent
Exclusion Criteria:
- Hypersensitivity to darunavir, cobicistat, or any excipients
- Patients with severe liver injury (Child-Pugh Class C)
- Concomitant medications that are highly dependent on CYP3A clearance, and the elevated
plasma concentrations are associated with serious or life-threatening events.
- Subjects were considered to be unable to complete the study, or not suitable for the
study by researchers
Exit criteria:
- Subjects asked to withdraw the study
- Subject will benefit if withdraw according to researchers' suggestions
Shanghai Public Health Clinical Center
Shanghai, Shanghai, China
Shanghai Public Health Clinical Center
Shanghai, Shanghai, China
Hongzhou Lu, Ph.D
+86-021-37990333 - 3222
luhongzhou@fudan.edu.cn
Hongzhou Lu, PI
+86-021-37990333 - 3222
luhongzhou@fudan.edu.cn